Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
The effects of tamsulosin treatment on changes in frequency-volume chart (FVC) data, especially nighttime urine production, over time were assessed, and the mechanisms underlying the improvement of nocturia in benign prostatic hyperplasia (BPH) patients with nocturnal polyuria (NP) are discussed.
A total of 104 patients with lower urinary tract symptoms secondary to BPH were enrolled. After enrollment in the study, the patients were treated with tamsulosin (0.2 mg) once daily. Visits were scheduled every 4 weeks until week 12 (month 3) after study entry, and then every 12 weeks subsequently. All patients completed the International Prostate Symptom Score (IPSS), quality of life (QOL) index, and 3-day FVC, and underwent uroflowmetry at enrollment and on each visit.
Eighty-two patients (mean age: 70.9 ± 7.1 years) were analyzed for 24 months after treatment. Patients were divided into two groups, NP and nonNP, based on FVC outcome. The IPSS, QOL index, and maximum flow rate improved during the 24-month period after treatment in both groups. Mean daytime urine volume significantly increased in the NP group, but no changes were detected in the nonNP group. Mean nighttime urine frequency significantly decreased in the NP group over a 24-month period, and was associated with a significant decrease in nighttime urine volume that was not found in the nonNP group. Maximum voided volume increased most months after treatment in both groups.
The present long-term prospective study using FVC demonstrated that tamsulosin reduced nighttime urine production in BPH patients with NP.
Written by:
Kojima Y, Sasaki S, Imura M, Kubota Y, Hayashi Y, Kohri K. Are you the author?
Reference: Neurourol Urodyn. 2011 Oct 28. Epub ahead of print.
doi: 10.1002/nau.21224
PubMed Abstract
PMID: 22038792
UroToday.com BPH and Male LUTS Section
